These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1111912

  • 1. Combination chemotherapy for disseminated malignant melanoma.
    Costanzi JJ, Vaitkevicius VK, Quagliana JM, Hoogstraten B, Coltman CA, Delaney FC.
    Cancer; 1975 Feb; 35(2):342-6. PubMed ID: 1111912
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ, Falkson G.
    Med Pediatr Oncol; 1975 Feb; 1(2):107-11. PubMed ID: 1228411
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of 1-(2-chloroethyl-3-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45338) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma.
    Ahmann DL, Hahn RG, Bisel HF.
    Cancer; 1974 Mar; 33(3):615-8. PubMed ID: 4131357
    [No Abstract] [Full Text] [Related]

  • 7. Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin.
    Gerner RE, Moore GE, Didolkar MS.
    Cancer; 1973 Oct; 32(4):756-60. PubMed ID: 4751912
    [No Abstract] [Full Text] [Related]

  • 8. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma.
    Carter SK, Friedman MA.
    Eur J Cancer (1965); 1972 Feb; 8(1):85-92. PubMed ID: 4552317
    [No Abstract] [Full Text] [Related]

  • 9. Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).
    Hill GJ, Ruess R, Berris R, Philpott GW, Parkin P.
    Ann Surg; 1974 Aug; 180(2):167-74. PubMed ID: 4601984
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
    Cohen SM, Greenspan EM, Ratner LH, Weiner MJ.
    Cancer; 1977 Jan; 39(1):41-4. PubMed ID: 832250
    [Abstract] [Full Text] [Related]

  • 16. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
    Einhorn LH, McBride CM, Luce JK, Caoili E, Gottlieb JA.
    Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
    [No Abstract] [Full Text] [Related]

  • 17. [Imidazole carboxamide in the treatment of disseminated melanoblastoma].
    Garin AM, Lichinitser MR, Moroz LV.
    Vopr Onkol; 1973 Oct; 19(11):3-7. PubMed ID: 4785973
    [No Abstract] [Full Text] [Related]

  • 18. Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
    Falkson G, van Eden EB, Falkson HC.
    Cancer; 1974 May; 33(5):1207-9. PubMed ID: 4595974
    [No Abstract] [Full Text] [Related]

  • 19. Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma.
    Nathanson L, Wolter J, Horton J, Colsky J, Shnider BI, Schilling A.
    Clin Pharmacol Ther; 1971 May; 12(6):955-62. PubMed ID: 5134998
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.